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Preoperative radiotherapy versus selective postoperative 
chemoradiotherapy in patients with rectal cancer (MRC CR07 
and NCIC-CTG C016): a multicentre, randomised trial
David Sebag-Monteﬁ ore, Richard J Stephens, Robert Steele, John Monson, Robert Grieve, Subhash Khanna, Phil Quirke, Jean Couture, 
Catherine de Metz, Arthur Sun Myint, Eric Bessell, Gareth Griﬃ  ths, Lindsay C Thompson, Mahesh Parmar, on behalf of all the trial collaborators*
Summary
Background Preoperative or postoperative radiotherapy reduces the risk of local recurrence in patients with operable 
rectal cancer. However, improvements in surgery and histopathological assessment mean that the role of radiotherapy 
needs to be reassessed. We compared short-course preoperative radiotherapy versus initial surgery with selective 
postoperative chemoradiotherapy. 
Methods We undertook a randomised trial in 80 centres in four countries. 1350 patients with operable adenocarcinoma 
of the rectum were randomly assigned, by a minimisation procedure, to short-course preoperative radiotherapy (25 Gy 
in ﬁ ve fractions; n=674) or to initial surgery with selective postoperative chemoradiotherapy (45 Gy in 25 fractions 
with concurrent 5-ﬂ uorouracil) restricted to patients with involvement of the circumferential resection margin 
(n=676). The primary outcome measure was local recurrence. Analysis was by intention to treat. This study is 
registered, number ISRCTN 28785842. 
Findings At the time of analysis, which included all participants, 330 patients had died (157 preoperative radiotherapy 
group vs 173 selective postoperative chemoradiotherapy), and median follow-up of surviving patients was 4 years. 
99 patients had developed local recurrence (27 preoperative radiotherapy vs 72 selective postoperative 
chemoradiotherapy). We noted a reduction of 61% in the relative risk of local recurrence for patients receiving 
preoperative radiotherapy (hazard ratio [HR] 0·39, 95% CI 0·27–0·58, p<0·0001), and an absolute diﬀ erence at 3 years 
of 6·2% (95% CI 5·3–7·1) (4·4% preoperative radiotherapy vs 10·6% selective postoperative chemoradiotherapy). We 
recorded a relative improvement in disease-free survival of 24% for patients receiving preoperative radiotherapy 
(HR 0·76, 95% CI 0·62–0·94, p=0·013), and an absolute diﬀ erence at 3 years of 6·0% (95% CI 5·3–6·8) (77·5% vs 
71·5%). Overall survival did not diﬀ er between the groups (HR 0·91, 95% CI 0·73–1·13, p=0·40).
Interpretation Taken with results from other randomised trials, our ﬁ ndings provide convincing and consistent 
evidence that short-course preoperative radiotherapy is an eﬀ ective treatment for patients with operable rectal cancer.
Funding Medical Research Council (UK) and the National Cancer Institute of Canada.
Introduction
Loco-regional recurrence after resection of rectal cancer is 
diﬃ  cult to treat and is associated with severe debilitating 
symptoms. The prognosis after a local recurrence is 
poor, with a median survival of 12–18 months.1,2
Randomised controlled trials published before 
1998 showed a high rate of local recurrence after surgery 
alone3–14 and a reduction in local recurrence with 
radiotherapy used either preoperatively3–9 or 
postoperatively.10–14 Of these trials, the Swedish rectal 
cancer trial7 was the largest (1168 patients) and showed 
that the addition of a 1-week (short) course of pelvic 
radiation (25 Gy in ﬁ ve fractions) before surgery resulted 
in a statistically signiﬁ cant reduction in local recurrence 
rate and improvement in overall survival compared with 
surgery alone (at 5 years: local recurrence 11% vs 27%, 
overall survival 58% vs 48%).
Chemotherapy can also be added to radiotherapy; the 
use of postoperative concurrent chemoradiotherapy 
reduced local recurrence rates14,15 and improved survival.15,16 
The consensus statement by the US National Institutes 
for Health in 199017 recommended postoperative chemo-
radiotherapy as standard treatment in the USA for all 
patients with completely resected stage II or III rectal 
cancer.
Nevertheless, pelvic radiotherapy is associated with an 
increased risk of late complications, including a 
substantial increase in bowel frequency and incon-
tinence18,19 and delayed healing of the perineal wound 
when an abdominoperineal excision is done.20 Therefore, 
targeting radiotherapy to patients considered at high risk 
of local recurrence is an attractive option, especially if the 
number of such patients can be kept to a minimum.
Specialist colorectal surgeons in individual centres 
reported improvements in surgical technique, using 
careful sharp dissection of the mesorectal tissues (total 
mesorectal excision), with 5-year local recurrence rates 
of less than 10%.21,22 Thus, at the end of the 1990s, two 
questions remained: did preoperative radiotherapy add 
anything to total mesorectal excision, and could 
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improved methods be found to identify the few patients 
at high risk postoperatively (rather than postoperative 
chemo-radiotherapy for all patients with stage II or III 
disease)?
Adam and colleagues23 described the histopathological 
assessment of the circumferential resection margin and 
showed that involvement of this margin (deﬁ ned as 
microscopic tumour present 1 mm or less from the radial 
margin) was associated with a high risk of local recurrence 
and poor survival. This method of assessment oﬀ ered 
much appeal since it could identify a few patients at high 
risk of failure who might beneﬁ t from selective 
postoperative chemoradiotherapy.
This trial was therefore designed to compare the use of 
routine short-course preoperative radiotherapy with 
initial surgery and selective postoperative chemo-
radiotherapy reserved for patients who had involvement 
of the circumferential resection margin.
Methods
Study design and patients
The Medical Research Council (MRC) CR07 and National 
Cancer Institute of Canada (NCIC) Clinical Trials Group 
C016 trial was a multicentre, randomised controlled trial 
comparing preoperative radiotherapy with selective 
postoperative chemoradiotherapy. Between March 16, 
1998, and Aug 5, 2005, eligible patients were recruited 
from 80 centres in four countries (69 UK, nine Canada, 
one South Africa, and one New Zealand). The protocol 
was approved in the UK by the Multicentre Research 
Ethics Committee for Scotland. Local ethics approval was 
obtained at all participating institutions, and written and 
informed consent was obtained from all patients. The 
MRC Clinical Trials Unit coordinated the trial, and 
an independent trial steering committee oversaw the 
trial. Conﬁ dential interim analyses were reviewed 
approximately every year during the recruitment period 
by an independent data monitoring committee.
Eligible patients had histologically conﬁ rmed adeno-
carcinoma of the rectum (deﬁ ned as the distal tumour 
less than 15 cm from the anal verge measured by rigid 
sigmoidoscopy) with no evidence of metastases 
(identiﬁ ed by liver ultrasound or CT scan and chest 
radiograph). The primary tumour had to be deemed 
resectable (deﬁ ned as not ﬁ xed to the pelvis and that 
complete excision was feasible). If operability could not 
be established by digital examination, examination 
under anaesthetic, supplemented when appropriate by 
pelvic CT or MRI scanning or by endoluminal ultrasound, 
was recommended. Patients had to be regarded as 
suﬃ  ciently ﬁ t to receive all treatments (an upper age 
limit was not deﬁ ned), and those with previous or 
present malignant disease that was likely to interfere 
with protocol comparisons were regarded as ineligible.
Eligible consenting patients were randomly assigned 
to treatment groups by the MRC Clinical Trials Unit by 
a minimisation procedure, with stratiﬁ cation for 
surgeon, distance of distal tumour extent from the anal 
verge, and WHO performance status. Patients were 
assigned to either a preoperative radiotherapy regimen 
of 25 Gy in ﬁ ve consecutive daily fractions followed by 
surgery (recommended to take place within 7 days of the 
last fraction of radiotherapy), or to a selected post-
operative chemoradiotherapy regimen of initial surgery 
with selective postoperative concurrent chemo-
radiotherapy of 45 Gy in 25 fractions with concurrent 
5-ﬂ uorouracil (either continuous infusion 200 mg/m² 
per day or weekly bolus 5-ﬂ uorouracil 300 mg/m² and 
leucovorin 20 mg/m²) for patients with involvement of 
the circumferential resection margin (≤1 mm).
Procedures
Surgeons were encouraged to use total mesorectal 
excision, although it was not mandated in the trial protocol. 
This approach was already in clinical use in the UK at the 
time that the trial was launched. No formal training or 
accreditation programme was used for surgeons 
participating in the trial. At the time of trial design, a 
validated audit method to assess whether total mesorectal 
excision was done, or to assess the quality of the surgical 
specimen, did not exist. However, a simple grading 
system of the resected macroscopic surgical specimen 
was prospectively assessed as part of the trial and the 
results are presented in an accompanying article.24
The radiotherapy target volume was deﬁ ned as the 
sacral promontory superiorly, 3–5 cm below the inferior 
tumour extent, 2–3 cm anterior to the sacral promontory, 
1 cm posterior to the anterior sacrum, and 1 cm lateral 
to the most lateral aspect of the bony true pelvis. 
Whenever possible, the anal canal was to be spared in 
patients with mid and upper rectal cancer. The perineal 
scar was to be included postoperatively in patients with 
tumours less than 5 cm from the anal verge.
Adjuvant chemotherapy could be given with either a 
monthly (5-ﬂ uorouracil 370–425 mg/m² on days 1–5 every 
28 days) or weekly (5-ﬂ uorouracil 370–425mg/m² once 
per week) schedule combined with 20 mg/m² leucovorin 
with each 5-ﬂ uorouracil administration. Centres were 
required to state their local policy for the use of adjuvant 
chemotherapy according to circumferential resection 
margin and lymph node status, which was to be applied 
to both treatment groups. If both postoperative 
chemoradiotherapy and adjuvant chemotherapy were 
required, postoperative chemoradiotherapy was to be 
given ﬁ rst.
After randomisation, follow-up forms were required at 
3, 6, 9, and 12 months, and then every 6 months to 3 years 
and yearly thereafter. Patient-reported quality of life was 
collected with the validated questionnaires SF36,25 and 
EORTC (European Organisation for Research and 
Treatment of Cancer) quality-of-life questionnaire 
CR-38,26 which were administered at baseline (before 
randomisation) and at the same timepoints as the clinical 
data, up to 36 months.
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Outcome measures
The primary outcome measure was local recurrence, 
irrespective of any occurrence of distant metastases. The 
time to local recurrence was deﬁ ned as the time from 
randomisation to a conﬁ rmed local recurrence. Con-
ﬁ rmed local recurrence was deﬁ ned as intraluminal 
tumour conﬁ rmed by a biopsy sample, positive imaging, 
or equivocal pelvic imaging with a raised serum 
carcino-embryonic antigen without distant metastases. 
Patients without a conﬁ rmed local recurrence were 
censored at the time of last follow-up.
Secondary outcome measures were overall survival, 
disease-free survival, local-recurrence-free survival, time 
to appearance of distant metastases, postoperative 
morbidity, quality of life, and long-term complications.
Overall survival was deﬁ ned as the time from 
randomisation to death from any cause, with survivors 
being censored at the time of last follow-up. Disease-free 
survival was deﬁ ned as the time from randomisation to 
conﬁ rmed local recurrence, distant metastases, or death 
due to disease or treatment, whichever occurred ﬁ rst. 
Patients who were alive and disease free (or died of a 
non-rectal-cancer cause with no evidence of disease) were 
censored at the time of last follow-up.
In this paper we report the primary outcome measure 
(local recurrence) and related secondary outcome 
measures (disease-free and overall survival), and put 
these results into context. Although quality of life is an 
important consideration when comparing treatments for 
rectal cancer, the analyses, presentation, and 
interpretation of quality-of-life data are complex. Initial 
analyses have been recently presented27 and a separate 
paper is in preparation. 
Statistical analysis
At the start of the trial, the standard of care in most of the 
UK was considered to be preoperative radiotherapy. 
This trial was therefore initially designed to establish 
whether selective postoperative chemoradiotherapy 
would be no worse than preoperative radiotherapy. The 
local recurrence rate for preoperative radiotherapy was 
estimated as approximately 10% at 2 years. To show non-
inferiority and reliably exclude a diﬀ erence of less than 
5% at 2 years with selective postoperative chemo-
radiotherapy, 1800 patients were required (two-sided log-
rank test, α=0·05, power=90%). In 2001, and on the basis 
of the evidence of a lower than expected local-recurrence 
rate in a large randomised trial,28 the sample size was 
revised to exclude a diﬀ erence of more than 2·5% in the 
local-recurrence rate at 2 years, assuming a 2-year 
local-recurrence rate of 2·5% with preoperative 
radiotherapy, which required 1350 patients (one-sided 
log-rank test, α=0·05, power=90%).
However, by 2006, most UK clinicians were using 
selective postoperative chemoradiotherapy, and therefore 
we took a decision to analyse the results in terms of 
superiority of preoperative radiotherapy over selective 
postoperative chemoradiotherapy. The 1350 patients were 
suﬃ  cient to reliably detect a 2·5% improvement in the 
local-recurrence rate at 2 years with preoperative radio-
therapy, from 5% with selective postoperative chemo-
radiotherapy to 2·5% with preoperative radio therapy 
(two-sided log-rank test, α=0·05, power=80%).
All analyses were by intention to treat. We compared 
proportions with the χ² test, and ordered categorical 
variables by the Mann-Whitney test. Survival curves of 
local-recurrence-free interval, disease-free survival, and 
overall survival were calculated by the Kaplan-Meier 
method and compared with a two-sided log-rank test. 
Potential diﬀ erences between preoperative radiotherapy 
and selective post operative chemoradiotherapy across 
subgroups were compared by a test for interaction for 
groups with two levels and a test for trend for groups with 
three or more levels. All hazard ratios (HRs) have been 
calculated in relation to the preoperative radiotherapy 
group to show the hazard associated with this treatment 
compared with selective postoperative chemoradiotherapy. 
1350 patients enrolled
1350 randomised
674 allocated to preoperative radiotherapy 676 allocated to selective postoperative CRT
Preoperative radiotherapy (25 Gy)
614 (96%) received 25 Gy
10 (1%) received more or  less than 25 Gy
14 (2%) no radiotherapy given
4 (<1%) details unknown
32 missing
Surgery
606 (97%) surgical resection
6 (1%) stoma only
8 (1%) other
5 (1%) no resection
49 missing
533 (90%) CRM
negative
57 (10%) CRM
positive
84 no resection
or missing
541 (88%) CRM
negative 
77 (12%) CRM
positive
58 no resection
or missing
Surgery
631 (97%) surgical resection
9 (1%) stoma only
6 (1%) other
3 (1%) no resection
27 missing
No postoperative CRT
494 (96%) no CRT
15 (3%) CRT
4 (1%) radiotherapy only
28 missing
674 analysed for main outcome measures
(including conﬁrmed local recurrence, disease-free
survival, and overall survival) (on an ITT basis)
676 analysed for main outcome measures
(including conﬁrmed local recurrence, disease-free
survival, and overall survival) (on an ITT basis)
Postoperative CRT
53 (69%) CRT
7 (9%) radiotherapy only
15 (22%) no radiotherapy
2 missing
Figure 1: Trial proﬁ le
CRT=chemoradiotherapy. CRM=circumferential resection margin. ITT=intention to treat.
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Quotation of landmark values, such as the median, directly 
from the Kaplan-Meier plots can be very misleading, since 
the curves might randomly converge or separate at the 
crucial timepoint. We have therefore used the result from 
the preoperative radiotherapy group and applied the HR 
for the whole curve to provide an estimate of the values for 
the selective postoperative chemoradiotherapy group. This 
method assumes proportional hazards but is more 
accurate than reading oﬀ  the curve.29
This study is registered, number ISRCTN 28785842. 
Role of the funding source 
The sponsor of the study had no role in the design and 
conduct of the trial, or in the analysis of the data. The 
corresponding author had full access to the data and had 
ﬁ nal responsibility for the decision to submit for 
publication.
Results
1350 patients were recruited and randomised 
(674 pre operative radiotherapy group, 676 selective 
postoperative chemoradiotherapy group). The median 
number of patients per centre was six (IQR two to 17), 
although 814 (60%) were treated in 12 centres that 
contributed 30 or more patients. Figure 1 shows the trial 
proﬁ le. Six patients did not meet the eligibility criteria:
two in the preoperative radiotherapy group (not cancer, 
unﬁ t) and four in the selective postoperative chemo-
radiotherapy group (unﬁ t, metastases present [two 
patients], previous malignancy), but these patients have 
been included in all analyses. Table 1 shows the baseline 
characteristics of patients.
628 patients (98% of the 642 patients with avail able 
data) received preoperative radiotherapy (ﬁ gure 1). 
14 (2%) patients did not receive any radiotherapy, because 
of other disease being present (n=5), problems with 
radiotherapy administration (3), patient choice (1), patient 
death (1), and unknown reasons (4). The median time 
from the end of radiotherapy to surgery was 4 days (IQR 
3–6), and 524 (91% of the 578 patients with available 
surgery and radiotherapy data) had their surgery within 
7 days of radiotherapy.
The median time from randomisation to surgery was 
27 days (IQR 21–33) in the preoperative radiotherapy 
group and 19 days (IQR 12–26) in the selective 
postoperative chemoradiotherapy group. Surgical 
resection was done in 1237 patients (97% of the 
1274 patients with data available; ﬁ gure 1), and 
1143 (92%) of these resections were recorded as total 
mesorectal excision by the operating surgeon. In 
patients who had an anterior resection, the clinical 
anastomotic leak rates at 1 month were similar in both 
groups (preoperative radiotherapy: 9% [95% CI 6–12], 
selective postoperative chemoradiotherapy: 7% [4–9]). 
However, in patients who had an abdominoperineal 
excision, more of those in the preoperative than in the 
selective postoperative group were reported as having a 
non-healing perineum (70/202 [35%] vs 44/202 [22%]). 
Longer-term follow-up (in patients with an abdomino-
perineal excision) at 12 and 24 months showed that 
rates of small bowel obstruction, perineal wound failure 
to heal, and lumbar or sacral neuropathy did not diﬀ er 
between the two treatment groups (data not shown). 
The 30-day postoperative mortality rate was 2% 
Number at risk
Preoperative radiotherapy
Selective postoperative
chemoradiotherapy
Number at risk
Preoperative radiotherapy
Selective postoperative
chemoradiotherapy
Number at risk
Preoperative radiotherapy
Selective postoperative
chemoradiotherapy
Preoperative radiotherapy
Selective postoperative
chemoradiotherapy
Preoperative radiotherapy
Selective postoperative
chemoradiotherapy
Preoperative radiotherapy
Selective postoperative
chemoradiotherapy
A
C
B
0·2
0·4
0·6
Total
674
676
Events
27
72
674
676
587
594
477
462
342
334
242
216
137
120
HR=0·39 (95% CI 0·27–0·58); p<0·0001
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674
676
Events
147
189
HR=0·76 (95% CI 0·62–0·94); p=0·013
Total
674
676
Events
157
173
HR=0·91 (95% CI 0·73–1·13); p=0·40
0
0·8
1·0
1·0
1·0
0
0·2
0·4
0·6
0·8
674
676
556
557
437
418
316
310
225
198
129
114
0
0·2
0·4
0·6
0·8
0 1 2 3 4 5
Time (years)
593
608
486
490
347
361
245
234
139
126
674
676
Figure 2: Proportion of patients with a conﬁ rmed local recurrence (A), disease-free survival (B), and overall 
survival (C)
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(95% CI 1–3) in both groups. Of the 792 patients who 
had an anterior resection, 317 (83%) in the preoperative 
radiotherapy group and 318 (78%) in the selective 
postoperative chemoradiotherapy group were reported 
as having a defunctioning stoma.
The rate of circumferential resection margin 
involvement (table 1) and the proportion of patients with 
pathological stage III disease did not diﬀ er between the 
two groups (p=0·12 and p=0·29, respectively). However, 
we noted some evidence of a small downstaging eﬀ ect on 
T stage (p=0·0001) in the preoperative radiotherapy 
group, since there were 9% more patients with 
stage I disease and 6% fewer with stage II disease than in 
the selective postoperative chemoradiotherapy group.
Of the 646 patients allocated to receive selective 
postoperative chemoradiotherapy and who had a 
resection, 77 (12%) had involvement of the circum-
ferential resection margin. Of these 77 patients, 53 (69%) 
received chemoradiotherapy, seven (9%) received 
radiotherapy only, 15 (19%) had no radiotherapy, and 
two had no treatment data. Only one of the 53 patients 
who received chemoradiotherapy had any interruptions 
to their treatment as a result of toxic eﬀ ects from 
treatment. The median time from surgery to start of 
chemo radiotherapy was 57 days (IQR 43–72). Of those 
who had a negative circumferential resection margin, 
494 (91%) had no radiotherapy, 15 (3%) received 
chemoradiotherapy, and four (1%) received radiotherapy 
only. Treatment data were not available for the remaining 
28 (6%) patients.
Adjuvant chemotherapy was given to 235 of 585 
(40%) patients in the preoperative radiotherapy group 
and 274 of 609 (45%) in the selective postoperative 
chemo radiotherapy group. 138 (27%) received the 
monthly regimen (64/235 [27%] in the preoperative 
radiotherapy group, 74/274 [27%] in the selective 
postoperative chemoradiotherapy group), and 320 (63%) 
received the weekly regimen (144/235 [62%] vs 
176/274 [64%]). The remaining 51 (10%) patients 
received a variety of other adjuvant regimens. Adjuvant 
chemotherapy was given to 28 (18%) and 37 (18%) of 
patients with stage II disease, and 201 (84%) and 
232 (87%) of those with stage III disease in the 
preoperative radiotherapy and selective postoperative 
chemoradiotherapy groups, respectively.
Table 2 and ﬁ gure 2 show the results for local 
recurrence, disease-free survival, and overall survival. 
99 patients (27 preoperative radiotherapy group vs 
72 selective postoperative chemoradiotherapy group) 
developed a conﬁ rmed local recurrence. It was the only 
reported site of recurrence in 54 patients (13 vs 41), and 
occurred before (one vs 11), concurrently with (ten vs 
eight), or after (three vs 12) distant metastases in the 
remaining patients. Comparison of the Kaplan-Meier 
curves (ﬁ gure 2A) gives an HR of 0·39 (95% CI 
0·27–0·58; p<0·0001), indicating a 61% relative reduction 
in the risk of recurrence with preoperative radiotherapy. 
This ﬁ nding translates to an absolute diﬀ erence in the 
3-year local-recurrence rate of 6·2% (95% CI 5·3–7·1) 
(4·4% in the preoperative radiotherapy group vs 10·6% in 
the selective postoperative chemoradiotherapy group).
Preoperative radiotherapy 
(n=674)
Selective postoperative 
chemoradiotherapy (n=676)
Before treatment
Median age (range [years]) 65 (38–87) 65 (36–87)
Sex
Men 499 (74%) 482 (71%)
Women 175 (26%) 194 (29%)
WHO performance status
0 535 (79%) 534 (79%)
1 134 (20%) 135 (20%)
2 4 (<1%) 7 (1%)
3 1 (<1%) 0
Distance of distal tumour extent from anal verge (cm)
>10–15 95 (14%) 112 (17%)
>5–10 345 (52%) 337 (50%)
0–5 229 (34%) 217 (33%)
Missing 5 10
Type of surgery
Anterior resection 383 (61%) 409 (63%)
Abdominoperineal excision 202 (32%) 202 (31%)
Hartmann’s 21 (3%) 20 (3%)
Other 14 (2%) 15 (2%)
None 5 (1%) 3 (1%)
Missing 49 27
After treatment
Patients with a known resection 620 646
Operative mortality
30 day 12 (2%) 15 (2%)
60 day 17 (3%) 20 (3%)
Clinical anastomotic leak (anterior resection only)
Yes 32 (9%) 26 (7%)
No 338 (91%) 370 (93%)
Missing 13 13
Circumferential resection margin*
Involved 57 (10%) 77 (12%)
Not involved 533 (89%) 541 (88%)
Missing 30 28
Number of lymph nodes†
≥10 340 (57%) 426 (68%)
<10 257 (43%) 202 (32%)
Missing 23 18
TNM stage‡
I 183 (31%) 140 (22%)
II 169 (28%) 215 (34%)
III 239 (40%) 269 (43%)
IV 5 (1%) 5 (1%)
Missing 24 17
Data are number (%), unless otherwise indicated. *p=0·12. †p<0·0001. ‡p=0·034.
Table 1: Clinical, surgical, and histopathological details
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147 disease-related events were recorded in the pre-
operative radiotherapy group and 189 in the selective 
postoperative chemoradiotherapy group. Comparison of 
the Kaplan-Meier curves (ﬁ gure 2B) gives an HR of 
0·76 (95% CI 0·62–0·94; p=0·013), indicating a 
24% relative reduction in the risk of a disease-related event 
with preoperative radiotherapy. This ﬁ nding translates to 
an absolute diﬀ erence in 3-year disease-free survival of 
6·0% (95% CI 5·3–6·8) (77·5% in the preoperative group 
vs 71·5% in the selective postoperative group).
330 patients died (157 in the preoperative group, 173 in 
the selective postoperative group), and the median 
follow-up for surviving patients is 4 years. Comparison of 
the Kaplan-Meier curves (ﬁ gure 2C) gives an HR of 
0·91 (95% CI 0·73–1·13; p=0·40), indicating no 
signiﬁ cant diﬀ erence between treatment groups.
A few variables were explored (involvement of 
circumferential resection margin, distance of tumour 
from anal verge, and TNM stage; table 2) to investigate 
any variation of the treatment eﬀ ect across subgroups on 
rates of local recurrence. We detected no evidence of any 
interactions across any of the variables, although we 
acknowledge that the power to detect any interactions is 
low because of the small number of events.
Discussion
This trial was designed to compare the rates of local 
recurrence with two adjuvant radiotherapy regimens in 
patients with resectable rectal cancer. Results show that 
both local control and disease-free survival are improved 
by preoperative radiotherapy compared with selective 
postoperative chemoradiotherapy. The signiﬁ cant 
improvement in 3-year disease-free survival seems to be 
predominantly attributable to the reduction in local 
recurrence, although we noted a small non-signiﬁ cant 
reduction in both the number of patients with distant 
metastases and with deaths related to rectal cancer. At 
present there is no clear evidence of a diﬀ erence in 
overall survival, although there are fairly few deaths so 
far, and any diﬀ erence might be diluted by the large 
proportion (42%) of non-cancer deaths.
Trials undertaken before the introduction of total 
mesorectal excision strongly lent support to the 
preoperative radiotherapy regimen. Similarly, the selective 
postoperative chemoradiotherapy regimen was supported 
by studies showing a low rate of local recurrence after 
surgery and a highly selective approach to post operative 
chemo radiotherapy, allowing most patients to avoid 
radiotherapy.
Although total mesorectal excision was not mandated 
within the trial design, surgeons considered that it had 
been achieved in 93% of patients who underwent 
resection. No formal surgical training programme was 
used for centres participating in the trial. However, the 
overall negativity rate for circumferential resection 
margin was 89%, which compares favourably with the 
Dutch trial in which 77% of patients in the 
intention-to-treat analysis had tumour-free margins 
without tumour spillage.28 Quirke and colleagues24 
present the assessment of the surgical resection plane 
achieved and its correlation with outcome in the 
accompanying paper; they show that 86% of surgical 
specimens were done in the mesorectal or intramesorectal 
plane. The fairly high rate (32%) of abdominoperineal 
Preoperative 
radiotherapy 
(n=674)
Selective 
postoperative 
chemoradiotherapy 
(n=676)
HR (95% CI)
Disease-related events
Local recurrence criteria
Intraluminal tumour
Positive biopsy 2 23 ··
No biopsy 0 2 ··
Not intraluminal tumour
Positive imaging 15 25 ··
Positive biopsy 4 18 ··
Eq imaging, CEA+ve, M0 3 2 ··
Missing data 3 2 ··
Local recurrence (total) 27 (4%) 72 (11%) ··
Distant metastases 128 (19%) 139 (21%) ··
Disease-related death 89 (13%) 102 (15%) ··
Kaplan-Meier results*
Local recurrence ·· ·· 0·39 (0·27–0·58); p<0·0001
2 year 3·4% 8·3% ··
3 year 4·4% 10·6% ··
5 year 4·7% 11·5% ··
Disease-free survival ·· ·· 0·76 (0·62–0·94); p=0·013
2 year 82·5% 77·6% ··
3 year 77·5% 71·5% ··
5 year 73·6% 66·7% ··
Overall survival ·· ·· 0·91 (0·73–1·13); p=0·40
2 year 86·1% 84·8% ··
3 year 80·3% 78·6% ··
5 year 70·3% 67·9% ··
Eﬀ ects in subgroups
3-year local recurrence by CRM involvement†
Involved (positive) 13·8% 20·7% 0·64 (0·25–1·64)
Not involved (negative) 3·3% 8·9% 0·36 (0·23–0·57)
3-year local recurrence by tumour position (cm)‡
>10–15 1·2% 6·2% 0·19 (0·07–0·47)
>5–10 5·0% 9·8% 0·50 (0·28–0·90)
0–5 4·8% 10·4% 0·45 (0·23–0·88)
3-year local recurrence by TNM stage§
I 1·9% 2·8% 0·68 (0·16–2·81)
II 1·9% 6·4% 0·29 (0·12–0·67)
III 7·4% 15·4% 0·46 (0·28–0·76)
Eq imaging, CEA+ve, M0=equivocal imaging, abnormal carcino-embryonic antigen, and no metastases. 
CRM=circumferential resection margin. *The proportion of patients surviving in the selective postoperative 
chemoradiotherapy group has been calculated by applying the HR to the proportion in the preoperative radiotherapy 
group, to achieve a more reliable overall estimate. †Test for interaction p=0·29. ‡Test for trend p=0·21. §Test for trend 
p=0·93.
Table 2: Disease-related events and data for time to event
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excisions is not unexpected since a third of patients had 
a tumour less than 5 cm from the anal verge. We 
therefore believe that the outcome data from this trial 
are likely to represent that observed in routine clinical 
practice.
Most patients with stage III disease in this trial received 
adjuvant chemotherapy in keeping with standard 
practice in many countries, including the USA, with no 
real diﬀ erence in its use between treatment groups. 
Importantly, the proportion of patients with pathologically 
assessed stage III disease was the same in both groups, 
showing that no observed downstaging eﬀ ect of 
preoperative radiotherapy had occurred in terms of nodal 
status. Thus patients could be logically selected for 
postoperative adjuvant chemotherapy, which contrasts 
with the uncertainties surrounding selection for this 
treatment for patients who have undergone preoperative 
chemoradiotherapy and in whom substantial change in 
the histopathological stage might have occurred.
A Cochrane meta-analysis30 identiﬁ ed four phase III 
trials3,6,7,31 undertaken before the introduction of total 
mesorectal excision that used short-course preoperative 
25 Gy radiotherapy. Three trials3,6,7 compared short-course 
preoperative radiotherapy followed by surgery with 
surgery alone, although 316 of the 557 patients in the 
Stockholm II trial were also included in the Swedish 
Rectal Trial. The pooled data of the remaining two trials6,7 
show a highly consistent and signiﬁ cant reduction in the 
rate of local recurrence with the use of preoperative 
radiotherapy (HR 0·46, 95% CI 0·38–0·56; ﬁ gure 3). A 
similar beneﬁ t is also seen in the Uppsala trial31 that 
compared short-course pre operative radiotherapy with 
surgery followed by postoperative split-course radio-
therapy for patients with Dukes B and C histology. The 
Cochrane meta-analysis identiﬁ ed CR07 and the Dutch 
colorectal cancer group trial,28 which used short-course 
preoperative radiotherapy and total mesorectal excision 
(although only data from the Dutch trial were available 
at that time). Both trials assessed short-course 
preoperative radiotherapy with a highly selective 
postoperative radiotherapy regimen. The CR07 trial used 
postoperative concurrent chemo radiotherapy, whereas 
the Dutch trial used radiotherapy alone in the selective 
postoperative group. The combined data from the CR07 
trial and the Dutch trial (the two largest adjuvant 
radiotherapy trials, totalling 3211 patients) show a highly 
signiﬁ cant reduction in the rate of local recurrence with 
the use of preoperative radiotherapy (HR 0·38, 95% CI 
0·29–0·49) when combined with total mesorectal 
excision (ﬁ gure 3).
Very clear evidence now suggests that preoperative 
radiotherapy produces the same proportional reduction 
in the rate of local recurrence when combined with total 
mesorectal excision as that seen in previous studies 
undertaken before such excision. The preoperative 
radiotherapy regimen is also a very cost-eﬀ ective way to 
deliver treatment, since it uses only ﬁ ve fractions of 
radiation. Furthermore, evidence from the 13-year 
follow-up from the Swedish rectal cancer trial,32 and data 
from three meta-analyses,30,33,34 lend support to the view 
that preoperative radiotherapy prevents a proportion of 
patients from developing local recurrence rather than 
merely delaying the event.
However, clear evidence also suggests that long-term 
surgically-related morbidity is increased by both 
preoperative and postoperative radiotherapy. Previous 
studies have reported sexual dysfunction,33 long-term 
impairment of bowel function and incontinence,18,19,34 a 
signiﬁ cant delay in healing of the perineal wound after 
abdominoperineal excision,20 and an increased risk of 
second malignancy with the use of adjuvant 
radiotherapy.35 Furthermore, loss of fertility in men and 
premenopausal women inevitably occurs. The main 
measure of the long-term eﬀ ect of treatment in this trial 
was the use of prospective quality-of-life questionnaires. 
The initial results have been presented27 and suggest that 
sexual functioning seemed to be most aﬀ ected, mainly 
as a result of surgery, with worse sexual functioning after 
an abdominoperineal excision. However, sexual 
functioning was further reduced in patients who had an 
anterior resection after preoperative radiotherapy. 
Detailed analysis will be presented elsewhere.
The risk of late toxic eﬀ ects emphasises the need to 
identify patients in whom the beneﬁ t (prevention of 
incurable local recurrence) is balanced against the 
long-term side-eﬀ ects related to the radiotherapy. 
Unfortunately, none of the phase III trials of radiotherapy 
had suﬃ  cient power or a priori planned interaction 
analyses to adequately address this issue. The interaction 
analyses in this trial showed no evidence of a diﬀ erence 
in the beneﬁ t from preoperative radiotherapy when 
distance from the anal verge and TNM stage were 
considered, although the absolute diﬀ erence in local 
recurrence is greatest for patients with stage III disease.
Two recent phase III trials36,37 have shown a signiﬁ cant 
reduction in local recurrence with the use of preoperative 
Trial recruitment 1987–93 (before total mesorectal excision)
Stockholm I6
Swedish RCT7
Subtotal
Trial recruitment 1996–2005 (after total mesorectal excision)
All trials
Overall
Events/patients
Radiotherapy
+surgery
Surgery
61/424
63/553
124/977
37/924
27/674
64/1598
188/2575 445/2595 0·43 (0·37–0·50)
103/937
72/676
175/1613
120/425
150/557
270/982
0·51 (0·38–0·68)
0·42 (0·32–0·55)
0·46 (0·38–0·56)
0·36 (0·26–0·51)
0·39 (0·27–0·58)
0·38 (0·29–0·49)
HR (95% CI)
Radiotherapy
better
0·2 0·5 1·0
Radiotherapy
worse
Dutch TME37
CR07
Subtotal
Figure 3: Summary of reduction in risk of local recurrence in phase III trials that have assessed short-course 
preoperative radiotherapy with 5 Gy per fraction
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concurrent chemoradiotherapy with 5-ﬂ uorouracil and 
leucovorin compared with long-course radiotherapy alone. 
A further trial38 has shown a signiﬁ cant reduction in both 
local recurrence and late toxic eﬀ ects in favour of 
preoperative chemoradiotherapy compared with post-
operative chemoradiotherapy. This ﬁ nding has aﬀ ected 
the US policy of postoperative chemoradiotherapy, with a 
shift to the use of preoperative chemoradiotherapy in 
selected patients. These results suggest that a direct 
comparison of short-course preoperative radiotherapy and 
preoperative chemoradiotherapy is needed. One small 
Polish trial used this design with results showing no 
evidence of a diﬀ erence in the rates of sphincter preserving 
surgery39 (the primary outcome measure) or local 
recurrence,40 although it was not statistically powered to 
address local recurrence. An Australian trial41 has reported 
initial quality-of-life data, but outcome data are still 
awaited.
At the time that this trial was recruiting, evidence for 
the use of pelvic MRI to accurately assess stage of rectal 
cancer was insuﬃ  cient. (The results of the multicentre 
MERCURY study42,43 were published after the trial 
closed to recruitment.) Pelvic MRI and CT scans were 
used in the preoperative staging in 556 (41%) and 
812 (60%) of the patients in this trial, respectively, and 
examination under anaesthetic in 548 (41%). These 
factors suggest that there is scope for future studies 
that incorporate MRI staging and compare preoperative 
radiotherapy and chemoradiotherapy in a deﬁ ned 
population of patients whose margin of excision is not 
at risk.
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